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Background. Interleukin-4 (IL-4), a Th2 cytokine, can stimulate immunoglobulin E (IgE) transcription. No previous studies
evaluated the genetic mechanisms in nonatopic AA patients with elevated serum IgE. Objective. To compare serum IL-4 and
total IgE levels between Egyptian nonatopic AA patients and healthy subjects and to investigate a possible relation to HLA-DRB1
alleles. Results. Serum IL-4 and total IgE were measured by ELISA in 40 controls and 54 nonatopic AA patients. Patients’ HLA-
DRB1 typing by sequence speciﬁc oligonucleotide probe technique was compared to normal Egyptian population. We found
signiﬁcantlyelevatedserumIL-4andtotalIgEinAApatients(particularlyalopeciauniversalis,AU,andchronicpatients)(P<. 01).
HLA-DRB1∗11 is a general susceptibility/chronicity allele. DRB1∗13 is a protective allele. DRB1∗01 and DRB1∗07 are linked to
chronicity. Localized AA showed decreased DRB1∗03 and DRB1∗07. Extensive forms showed increased DRB1∗08 and decreased
DRB1∗04. Elevated IL4 and IgE were observed in patients with DRB1∗07 and DRB1∗11 not DRB1∗04. Conclusion. Serum IL-4
and IgE are elevated in nonatopic AA patients, particularly AU and chronic disease. Relevant susceptibility, chronicity, and severity
HLADRB1 alleles may have a role in determining type, magnitude, and duration of immune response in AA favouring increased
IL4 and IgE.
1.Introduction
Alopecia areata (AA) is an unpredictable, usually patchy,
nonscarring hair loss condition with any hair-bearing area
may be aﬀected [1]. Papadopoulos et al. classiﬁed AA
according to the extent of hair loss into: localized or patchy
AA (LAA), alopecia totalis (AT), with complete loss scalp
hair, and alopecia universalis (AU) with total body hair loss
[2]. Of the numerous pathogenic processes which have been
proposed to underlie the etiology of AA, immunological,
environmental, psychological, and genetic factors are the
most powerful explanations [3].
Although increased levels of T helper1 (Th1) cytokines
(interferon-γ,I F N - γ and interleukin-2, IL-2) in lesional AA
skin have been reported [4], Th2 immune response is also
incriminated in the pathogenesis of AA [5, 6]. Cytokines
derived from Th2 cells, for example, IL-4 and IL-13 can
stimulate the transcription of IgE in B-cells through Ig
constant region genes [7, 8]. Unfortunately, the mechanism
by which IgE might interact in the pathogenesis of AA is
unknown. One possible explanation is supported by the
immune status of AA [5]. However, Diﬀerent studies have
measured IgE in AA patients with controversial results [9,
10]. Another possibility to explain the elevation of total
serum IgE in AA patients is the genetic mechanisms of AA,
which seems to be polygenic, where several genes such as
IL-4 gene [8], and the gene for β subunit of type 1 IgE
receptor (Fcε RIβ)[ 6], play a role in determining the disease
susceptibility, and the associations of AA with atopic disease
[11]. However, to our knowledge, no previous studies were
done to evaluate the genetic mechanisms in nonatopic AA
patients with elevated serum IgE levels.
As is the case with many other autoimmune diseases,
there is an association between AA and HLA. The most
signiﬁcant associations between AA and HLA loci vary with
diﬀerentpopulationsasHLAantigensarepopulationspeciﬁc
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Therefore, the aim of this work was to compare serum
levels of IL-4 and total IgE between Egyptian patients with
diﬀerentclinicalformsofAAwithoutatopicbackgroundand
healthysubjects,andtoinvestigatetherelationbetweenthese
levels to the HLA-DRB1 proﬁle, the most frequent HLA-DR
alleles among Egyptians.
2.SubjectsandMethods
2.1. Subjects. After giving informed consent, 54 patients
with AA were included in the present study, collected from
the Dermatology Outpatient Clinic, Ain Shams University
Hospital during the period from July 2008 till June 2009.
They were 36 males and 18 females, and their age ranged
from 20 to 65 years. The control group consisted of 40 age-
and sex-matched generally healthy subjects, 26 males and 14
females, with no scalp lesions in their personal history or
on clinical examination. All subjects of the study (patients
and controls) were subjected to: full history taking and
dermatological examination including: search for possible
associations with AA such as atopic dermatitis and vitiligo
and clinical assessment of AA lesions including: number of
the lesions, site and size of the lesions, and classiﬁcation
according to clinical severity into: LAA, AT, and AU. All
subjects of the study were subjected to: stool analysis to
exclude parasitic infestation, complete blood count (CBC)
to determine the number of eosinophils, and skin prick test
to a panel of allergens. Patients using topical, intralesional,
or systemic agents as steroids or immunosuppressives likely
to cause regrowth in AA within the past month, patients
subjected to sessions of PUVA, for at least 6 months before
this study, and those having other types of illness such as
atopic diseases andparasitic infestationorthose whoshowed
positive response to skin prick test, that could aﬀect the
outcome of the study, were excluded.
2.2. Methods. Both patients and controls were subjected
to determination of serum IL-4 and total IgE levels using
enzyme-linked immunosorbent assay (ELISA) technique
(AviBion Human IL4 ELISA Kit. FINLAND for IL4 and
Monobind Inc. USA for IgE). The assay was performed in
a blind fashion on coded samples by an investigator who
was not informed of the subject’s clinical status, after the
collection of all samples had been completed. In healthy, non
allergic adults, reference range of IgE was up to 90IU/ml.
HLA-DRB1 typing was done for patients by sequence
speciﬁc oligonucleotide probe (SSOP) technique. Fiveml
blood on sterile EDTA tubes were collected from each
subject, and DNA extractions were done using GIFXTM
genomicbloodDNApuriﬁcationkit(AmershamBiosciences
Inc., USA). Typing was done using Dynal RELITM SSO
HLA-DRB typing kit (Dynal Biotech Ltd.,UK). Interpreta-
tion of the results was done using the Dynal RELITM SSO
pattern matching program [13]. To compare their results
with the normal population, control samples results were
taken from the study population by Khalil et al. [14]. Their
population included healthy unrelated Egyptian individuals
(age range 23–38 years) attending at the immunogenetics
and transplantation lab of Ain Shams University Specialized
Hospital as kidney donors for their relatives.
Data analysis was done using SPSS software package (V.
16, Echosoft Corp., USA). Qualitative data were analyzed
using Chi-square test while quantitative data were analyzed
by Kruskal-Wallis and Mann-Whitney test. Pearson correla-
tion coeﬃcient was done for IgE and IL-4. The probability
of error at 0.05 was considered signiﬁcant, while at 0.01 is
highly signiﬁcant.
3. Results
The study included 54 patients with AA; among them, there
were 18 patients (33.3%) with LAA, 18 (33.3%) with AT,
and 18 (33.3%) with AU. The duration of AA ranged from
2 weeks to 9 years with a mean of 18.4 months. Forty-one
patients (75.9%) had duration of disease of less than 1 year,
and13patients(24.1%)theirdiseaselastedmorethan1year.
There were 4 patients (7.4%) with positive family history
of AA. Ten patients (18.5%) showed a relation between the
onset of their disease and a preceding period of stress, while
44 (81.5%) stated no relation to stress.
Twenty-six (48.3%) of our patients had elevated IgE. was
statistically highly signiﬁcant increase in both IgE and IL-4
levelsinpatientscomparedtocontrolswasobserved(median
of 111 versus 21.1IU/ml and 49 versus 12pg/ml, resp.)
(Table 1). Table 2 showed that there is highly signiﬁcant
diﬀerence in IgE and IL4 levels among diﬀerent types of
Alopecia (both were statistically signiﬁcantly elevated in
AU patients, compared to both AT and LAA). By doing
Spearman correlation test between IgE and IL4 among
patients, it was clear that there is a statistically signiﬁcant
positive correlation (elevated IgE is associated with increased
IL4 level) (r = .963, P<. 01) (Figure 1). The data
presented in Table 3 indicated that there is a statistically
highly signiﬁcant increase in both IgE and IL4 levels in
chronic patients with disease duration more than 1 year, but
not with less than 1 year, in comparison to controls.
ConcerningthefrequenciesofselectedHLA-DRB1alleles
among patients and normal Egyptians, a statistically sig-
niﬁcant increase was elicited in patients regarding HLA-
DRB1∗11. In contrast, HLA-DRB1∗13 was signiﬁcantly
decreased among patients. LAA patients showed a statis-
tically signiﬁcant decrease regarding HLA-DRB1∗03 and
HLA-DRB1∗07, compared to controls. Comparing AT/AU
patients and normal controls, a statistically signiﬁcantly
increased HLA-DRB1∗08 and decreased HLA-DRB1∗04 was
found in patients (Table 4). In addition, AT/AU patients
showed signiﬁcantly decreased HLA-DRB1∗04 compared to
LAA (P = .003). Comparing patients with a disease duration
oflessandmorethan1year,bothofthegeneralsusceptibility
allele; HLA-DRB1∗11, and HLA-DRB1∗01 were linked to
chronicity. In addition, HLA-DRB1∗03 was found to protect
against chronicity, while HLA-DRB1∗07 predisposed to
prolonged disease duration (Table 5).
Using Chi square test, comparison of the frequencies
of selected HLA-DRB1 alleles in alopecia of less and more
than 1 year duration, in relation to IL-4/IgE levels, revealed
that IL-4/IgE levels were statistically highly signiﬁcantlyDermatology Research and Practice 3
Table 1: Comparison of IgE and IL-4 levels between cases and controls using Mann-Whitney test.
Cases n = 54 Controls n = 40 Z Mann Whitney P value
IgE: Median 111 21.1 4.470 <.001∗∗
(IU/ml) SEM 15.58 6.72
IL-4: Median 49 12 6.366 <.001∗∗
(Pg/ml) SEM 3.3 1.03
SEM: Standard error of mean
∗∗statistically highly signiﬁcant diﬀerence
Table 2:ComparisonbetweenIgEandIL4levelsindiﬀerentclinical
forms of AA using Kruskal-Wallis test.
Type of alopecia IgE (IU/ml) IL4 (Pg/ml)
AU Median 141.0 66.0
SEM 38.68 6.77
AT Median 111.0 49.0
SEM 6.81 2.62
LAA Median 25.0 13.0
SEM 10.14 4.5
Kruskal-Wallis 28.06 28.94
P value <.001∗∗ <.001∗∗
AT: alopecia totalis; AU: alopecia universalis; LAA: localized alopecia areata
SEM: Standard error of mean
∗∗statistically highly signiﬁcant diﬀerence
r = +0.963∗∗
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Figure 1: Correlation between serum IL-4 and IgE among the
studied patients.
elevated among the HLADRB1∗11 positive chronic patients
(having general AA susceptibility allele) and among the
HLADRB1∗07 positive chronic patients (harboring chronic-
ity allele) (Table 6). For HLADRB∗04, all patients had low
IL-4/IgE levels; 17 of them had a disease duration of less
than 1 year, while only one was a chronic case. Thus, there
are lowered levels of IL-4 and IgE in patients with HLA-
DR∗04 which was absent in AT/AU (antiseverity allele). In
other words, patients susceptible to AA, particularly chronic
and extensive disease, are also susceptible to increased IL-
4 and IgE levels. Other relevant alleles showed equivocal
frequencies with respect to IL-4/IgE levels.
Table 3: Comparison between IgE and IL4 levels in patients with
disease duration less and more than 1 year and controls using
Kruskal-Wallis test.
Duration class IgE (IU/ml) IL4 (Pg/ml)
Less than 1 year Median 34.0 28.0
SEM 9.06 3.02
More than 1 year Median 112.0 51.0
SEM 19.95 4.19
Control Median 21.1 12.0
SEM 6.72 1.03
Kruskal-Wallis 20.135 40.539
P value <.001∗∗ <.001∗∗
SEM: Standard error of mean
∗∗statistically highly signiﬁcant diﬀerence
4. Discussion
We investigated serum IL-4 and total IgE levels in AA
patients with exclusion of those with possible atopic disease
to evaluate the role of immune signals for IgE induction, in
AA patients, irrespective of atopic immune mechanisms. We
demonstrated that 48.3% of AA patients had elevated total
serum IgE, and that the mean serum levels of IL-4 and total
serum IgE were signiﬁcantly elevated in patients with AA in
comparison to normal controls. The association of serum
IgE levels and AA had been previously investigated with
varying results. O’Loughlin et al. analyzed serum IgE of 497
patients with various dermatological diseases including AA,
in comparison to 95 normal controls. They found elevated
total serum IgE in 30% of AA patients [12]. Przybilla et
al. found elevated total IgE in 19.7% of AA patients [9].
Kasumagi´ c-Halilov´ ıc and Prohi´ c, also found elevated total
I g Ei n2 2o f6 0( 3 7 % )o fA Ap a t i e n t s[ 10]. However, in
contrast to these results, total serum IgE levels were not
elevated in AA patients in other previous studies [11, 15].
The discrepancy between our results and the results of some
previous studies could be attributed to the diﬀerence in
inclusion and exclusion criteria, the diﬀerence in number of
patients involved, and to the diﬀerent environmental factors
which may inﬂuence IgE level.
In addition to B-cell antigen receptor stimulation, Th2
cytokines can switch on IgE production in AA [7, 8].
Teraki et al. found that serum levels of IL-1α and IL-4
were signiﬁcantly elevated in patients with the LAA, while
serum levels of IFN-γ and IL-2 were signiﬁcantly elevated in
patients with extensive forms [5] .T h es a m ew a ss u g g e s t e d4 Dermatology Research and Practice
Table 4: Frequencies of selected HLA-DRB1 alleles in alopecia patients compared to controls using Chi square test.
DRB1 allele Controls (n = 580) Overall alopecia (n = 54) P value LAA (n = 18) P value AT/AU (n = 36) P value
HLA-DRB1∗01 5% 5.6% .998 0% .083 5.6% .954
HLA-DRB1∗03 19% 22.2% .992 5.5% .000∗ 16.6% .515
HLA-DRB1∗04 16% 16.7% 1.0 11.1% .223 5.6% .006∗∗
HLA-DRB1∗07 6% 11.1% .31 0% .04∗ 11.1% .088
HLA-DRB1∗08 2% 5.6% .28 0% .911 5.6% .002∗∗
HLA-DRB1∗11 12% 22.2% .048∗ 11.1% .735 11.1% .735
HLA-DRB1∗13 16% 5.6% .021∗ 0% .00∗∗ 5.6% .003∗∗
HLA-DRB1∗15 7% 11.1% .459 5.5% .658 5.6% .658
AT: alopecia totalis; AU: alopecia universalis; LAA: localized alopecia ateata
∗statistically signiﬁcant diﬀerence
∗∗statistically highly signiﬁcant diﬀerence
Table 5: Frequencies of selected HLA-DRB1 alleles in Alopecia of
less than 1 year duration compared to alopecia with a duration of
more than 1 year using Chi square test.
DRB1 Allele Alopecia less than
1 year (n = 41)
Alopecia more than
1 year (n = 13) P value
HLA-DRB1∗01 0% 23.1% <.001∗∗
HLA-DRB1∗03 29.3% 0% .014∗
HLA-DRB1∗04 20.7% 3.8% .087
HLA-DRB1∗07 6.1% 26.9% .010∗∗
HLA-DRB1∗08 7.3% 0% .866
HLA-DRB1∗11 14.6% 46.2% .002∗∗
HLA-DRB1∗13 7.3% 0% .866
HLA-DRB1∗15 14.6% 0% .26
∗statistically signiﬁcant diﬀerence
∗∗statistically highly signiﬁcant diﬀerence
by Katagiri et al., who found that the levels of IFN-γ tended
to increase while the levels of IL-4 tended to decrease in
severe cases of alopecia [6]. In contrast, we found that total
serum IgE and IL-4 were elevated more in AU than in other
forms. This could be explained by the fact that previous
studies did not exclude patients with atopy and did not relate
cytokine proﬁle to disease chronicity. Thus, the speculation
of diﬀerent immune responses in LAA from the extensive
forms, being regulated by Th2 cytokines and Th1 cytokines,
respectively, needs further studies.
Our study provided a correlation between the onset of
AA and the level of IL-4 and IgE, since the longer the
disease duration was, the higher the levels of IL-4 and IgE
were present. Previous mouse and human data suggested
that the initiation phase of AA is a heavily Th1-biased
immune response, while the maintenance of destruction of
hair follicles by cytotoxic cells is due to a shift from a Th1
response to a more chronic Th2 immune proﬁle [16]. Thus,
AA is a cell-mediated autoimmune disease with late, possibly
secondary, humoral responses.
Regarding HLA-DRB1 proﬁle, our results suggest that
there is positive association between AA among Egyptian
patients and HLA-DRB1∗11. On the other hand, HLA-
DRB1∗13 is a protective allele. Besides, patients with HLA-
DRB1∗07 were likely to develop LAA, while patients with
HLA-DRB1∗03 were protected against it. Patients having
HLA-DRB1∗04 are less likely to develop the extensive forms,
while having HLA-DRB1∗08 make them susceptible to
extensive disease. In agreement with some of our results,
Broniarczyk-Dyla et al. identiﬁed DRB1∗03 as a protective
allele against AA [17]. Akar et al. found that the frequency of
DRB1∗03 was decreased in all Turkish patients group, while
DRB1∗04 was increased in patients with 25%–75% scalp
hair loss [18]. Morling et al. reported signiﬁcant association
between AA and DRB1∗1104 allele [19]. Colombe et al.
also identiﬁed increased DRB1∗1104 in all American AA
patients groups, but they found DRB1∗0401 (DR4) to
be signiﬁcantly increased uniquely in AT/AU patients [20,
21]. Barahmani et al. found DRB1∗1104 to be strongly
associated and DRB1∗0301 to be negatively associated with
AT/AU [22]. A signiﬁcant increase of DR4 was also reported
in Caucasian British AA patients by Zhang et al. [23].
Association with DR4 has also been found by several groups
[24–27].
We noticed that the general susceptibility allele; HLA-
DRB1∗11, and DRB1∗01 and DRB1∗07 were linked to
chronicity, while HLA-DRB1∗03 was found to protect
against disease chronicity. In contrast, Akar et al. found no
signiﬁcantdiﬀerenceinthefrequencyofHLAallelesbetween
early and late onset disease patients [18], while Orecchia et
al. did ﬁnd a correlation with DR5 (DR11) in Italian patients
[28].
HLA-DRB1∗11 and HLA-DRB1∗07 (general AA suscep-
tibility and chronicity alleles) were associated with elevated
levels of serum IL4 and IgE in chronic patients. However,
with HLA-DRB1∗4 (antiseverity allele) there were lowered
levels of both. This means that the relevant HLA-DRB1
alleles with respect to susceptibility, chronicity, and severity
of AA may have an important role in determination of
immune response, favouring increased IL4 and IgE. In other
words, patients susceptible to AA in general, and to the
chronic and severe forms in particular, are also susceptible
to increased IgE and IL4 levelsDermatology Research and Practice 5
Table 6: Comparison of the frequencies of selected HLA-DRB1 alleles in Alopecia of less and more than 1 year duration, in relation to
IgE/IL-4 level using Chi square test.
Allele Duration High IgE/IL-4 (n &% ) L o wI g E / I L - 4( n &% ) x2 P value
HLA-DRB1∗07 Less than 1 year 0 (0%) 5 (83%) 8.571 .003∗∗
More than 1 year 6 (100%) 1 (16.7%)
HLA-DRB1∗11 Less than 1 year 0 (0%) 12 (66.7%) 8.00 .005∗∗
More than 1 year 6 (100%) 6 (33.3%)
∗∗statistically highly signiﬁcant diﬀerence
5. Conclusion
In conclusion, serum IL-4 and IgE are signiﬁcantly elevated
in AA patients, particularly AU, irrespective of the presence
of atopy. Our study also provided a correlation between
the onset of AA and serum levels of IgE and IL-4. This
ﬁnding suggests a shift from a Th1 response in early AA
to a more chronic Th2 immune proﬁle, with secondary B-
cell stimulation and possible IgE class switching. Elevated
IgE and IL-4 could be related to the HLA proﬁle of
patients, which controls the type, magnitude, and duration
of immune response, contributing to disease susceptibility,
severity, and chronicity.
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